Sihuan Pharmaceutical Achieves Landmark Drug Approval for Advanced Breast Cancer Treatment

Key Highlights

• Marketing Approval Granted for Xuanyuening (Bireociclib Tablets) Third Indication: The National Medical Products Administration (NMPA) of China has approved Xuanyuening (Bireociclib Tablets), in combination with aromatase inhibitors (AIs), for the first-line treatment of HR+/HER2- advanced breast cancer.
• First and Only Drug in China Covering All Lines of Treatment: Bireociclib is now the first and only drug in China to cover first-line, second-line, and later-line treatments for HR+/HER2- advanced breast cancer.
• Significant Expansion of Patient Coverage and Clinical Value: The new indication substantially broadens patient access and enhances the clinical value and future sales potential of Bireociclib.

Details of the Approval and Clinical Data

The approval is based on the successful completion of the BRIGHT-3 Phase III clinical trial, a randomized, double-blind study conducted across 58 centers in China. The trial evaluated Bireociclib combined with letrozole or anastrozole for first-line treatment of HR+/HER2- advanced breast cancer.

• Clinical Efficacy: Interim analysis shows the median Progression-Free Survival (mPFS) for patients in the Bireociclib group has not yet been reached, outperforming the control group (18.43–19.55 months). Bireociclib reduced the risk of disease progression or death by 47% overall, and by 64% among patients with liver metastases—a population with poor prognosis.
• Objective Response Rate (ORR): The ORR in the Bireociclib group was 63.5%, compared to 42.5% in the control group.
• Safety Profile: The most common adverse events (diarrhea, neutropenia) were Grade 1–2 and effectively managed, indicating a favorable safety profile.

Market Potential and Competitive Advantage

• HR+/HER2- Breast Cancer Prevalence: Represents about 75% of all breast cancer cases in China. Approximately 30% are diagnosed at the advanced stage.
• Market Size: The CDK4/6 inhibitor market for HR+/HER2- advanced breast cancer in China is projected to reach RMB 13 billion by 2032.
• Bireociclib’s Unique Position: As the first approved CDK2/4/6 inhibitor in China, Bireociclib offers multi-target synergistic action, potent tumor suppression, and lower hematological toxicity compared to traditional CDK4/6 inhibitors.
• National Reimbursement Drug List: As of December 2025, Bireociclib’s two previous indications have been included in the National Reimbursement Drug List, effective January 1, 2026, increasing accessibility and potential sales volume.
• Global Market Leadership: Bireociclib is ranked first in the global CDK2/4/6 inhibitor market.

Corporate Overview and Strategic Position

Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of Sihuan Pharmaceutical, is focused on innovation in major disease areas such as oncology, digestion, and non-alcoholic steatohepatitis. The company employs two R&D platforms (small molecule chemistry and large molecule biologics) and maintains a deep product pipeline, including antibody-drug conjugates (ADCs).

Sihuan Pharmaceutical Holdings Group Ltd. (Stock Code: 0460) was founded in 2001 and listed in 2010. It operates a dual business strategy across medical aesthetics and biopharmaceuticals, supported by robust R&D, registration capabilities, efficient production platforms, and a mature sales system. The company aims to become a leading player in both medical aesthetics and biopharmaceuticals in China.

Potentially Price Sensitive Information for Investors

• First-Line Treatment Approval: The expansion to first-line treatment is a major milestone, likely to drive significant sales growth and market share for Bireociclib.
• Broader Patient Coverage: The approval makes Bireociclib the only drug covering the entire treatment spectrum for HR+/HER2- advanced breast cancer in China.
• Reimbursement Inclusion: Being listed in the National Reimbursement Drug List is expected to boost accessibility and further drive sales.
• Favorable Clinical Data: Strong efficacy and safety results may reinforce market adoption and confidence among clinicians.
• Market Leadership and Growth Potential: Given the large and growing market for HR+/HER2- breast cancer treatments and Sihuan’s competitive advantage, this news is highly likely to positively impact share value.

Management and Governance

The Board is chaired by Dr. Che Fengsheng, with a team of experienced executives and independent non-executive directors overseeing company operations and strategic direction.

Conclusion

The approval of Xuanyuening (Bireociclib Tablets) for first-line treatment of HR+/HER2- advanced breast cancer represents a pivotal moment for Sihuan Pharmaceutical. It is both a major clinical milestone and a potentially transformative commercial opportunity, positioning the company for accelerated growth and enhanced shareholder value. Given the breadth of coverage, strong clinical data, and market potential, this announcement is highly price sensitive and could significantly influence the company’s share value in the near to medium term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The information presented is based on company announcements and public data as of the date of publication and may be subject to change.

View SIHUAN PHARM Historical chart here